Abstract 84P
Background
Several studies showed that sex is a biological variable that influence immune response in several types of solid tumors; however, there is scarce information in hematological malignancies. In this work, we evaluate differences in immune cells compositions and immune response of multiple myeloma between sexes.
Methods
We conducted a computational biology study using transcriptomic data obtained from bone marrow aspiration collected from untreated multiple myeloma patients under the MMRF-COMMPASS protocol (study accession phs000748). Data was pre-processed and the expression levels were normalized to TPM (transcript per million). To evaluate differences in immune cells compositions, we quantified the immune cell in the tumor microenvironment with the analytic platform CIBERSORT. Differences in activated immune pathways was evaluated with the gene set enrichment analysis (GSEA). Pre-processed counts were normalized to TMM (trimmed mean of M-values) and GSEA was performed using the GSEA java desktop application (v4.3.2). In both analysis, patterns of immune gene sets and the immune cell composition were compared between tumors from female vs. male patients. A p<0.05 and a FDR<25% were considered statistically significant for GSEA analysis, while a p<0.05 and a FDR<0.05 6.1x10-5 was considered statistically significant for CIBERSORT analysis.
Results
Overall, 451 males and 313 female patients were included. We detected in samples from female patients an enrichment of dendritic cells activated (p=0.0023, FDR=0,0257) and NK cells activated (p=0.0059, FDR=0,0326). In contrast, we observed in male patients an enrichment of monocytes (p=6.10x 10 -5 , FDR=0,0013) and macrophages M1(p=0,0050, FDR=0,0326). The GSEA analysis revealed an overregulation of natural killer cell degranulation (p=0.007, FDR=0.21624), positive regulation of type I interferon mediated signaling pathway (p<0.0001, FDR=0.23946), and regulation of natural killer cell proliferation (p=0.01, FDR=0.2495).
Conclusions
The computational analysis showed some differences in the immune microenvironment, between sexes in multiple myeloma. Studies about the influence of these differences in the clinical outcomes of patients should be evaluated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09